What is Cerebrolysin?


Cerebrolysin® is mixture of peptides (proteins) from the brain of pigs – and it’s all compatible with humans (some insulins people have to inject are made from pigs also). Studies report that Cerebrolysin is effective for various brain/vascular and neurodegenerative disorders, including stroke, TBI (traumatic brain injury), dementia, Alzheimer’s, and other forms of cognitive impairment. [i],[ii],[iii],[iv],[v],[vi][vii],[viii],[ix],[x],[xi],[xii]

Cerebrolysin is manufactured by Ever NeuroPharma in Austria. While Cerebrolysin is not FDA approved in the United States, it is approved in many European and Asian countries for stroke, dementia and traumatic brain injury. It is available by prescription from your doctor.

What is a peptide?


Peptides are a chain of amino acids – fragments of proteins – like arginine, cysteine, glutamine, glycine. They are found in every human cell and are reported to have positive health benefits when used appropriately. The FDA does not regulate peptides, so that is why it is important to see a qualified healthcare professional in order to get a proper diagnosis before using any peptide product. Peptides should only be purchased from a licensed and qualified compounding Pharmacy with a valid prescription.

How Does It Work?


Cerebrolysin® improves the brain’s ability for self-repair by stimulating nerve growth. Cerebrolysin is reported to have neurotrophic (growing nerve cells) action similar to our own nerve growth factors (NGF) causing stimulation of sensitive neurons (brain cells). Cerebrolysin improves efficiency within the brain’s metabolic processes and is neuroprotective.

There are quite a few clinical trials that report Cerebrolysin is effective in improving cognitive function in stroke and dementia, but the evidence is limited for healthy adults and no studies have tested whether Cerebrolysin can prevent dementia.

How Do I Use Cerebrolysin?


If your doctor wants you to use Cerebrolysin, you will either get injections or an IV infusion at a clinic or at home.

If using SubQ dosing:

  • The normal SQ dosage is 1ml daily
  • Recommended injection site is the abdomen; rotate sites (don’t use the same place more than once without changing locations).
  • Do not inject Selank into scar tissue, bruises or your navel.
  • Do not share needles or syringes with other people.
  • Keep all medications out of the reach of children.

Are There Any Side Effects or Problems?


Cerebrolysin is reported safe in recommended dosages and side effects are not common and may include:

  • Loss of appetite
  • Nausea/vomiting
  • Injection site redness and burning

Make sure to let your doctor know before using Cerebrolysin if you:

  • Have any allergies
  • Have epilepsy or a history of seizures
  • Have a history of kidney problems
  • Are taking antidepressants called MAOIs [including Isocarboxazid (Marplan); Phenelzine (Nardil); Selegiline (Emsam); Tranylcypromine (Parnate)]
  • Are pregnant or nursing

DISCLAIMER: Statements made are for educational purposes and have not been evaluated by the US Food and Drug Administration (FDA). They are not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or disease, please talk to your doctor prior to using the recommendations given. ONLY purchase peptide products from Licensed Compounding Pharmacies and ONLY use peptides with a valid prescription and under the direct supervision of a qualified medical practitioner.

References


[1] Ladurner G., et al. Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomized controlled trial, J Neural Transm. 2005;112(3):415-428.

[2] Muresanu DF, et al. Cerebrolysin and recovery after stroke (CARS): A randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2015;47(1):151-9.

[3] Heiss et al. Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double blind, placebo-controlled, randomized trial. Stroke 2012;43(3):630-6.

[4] König Pet al., Cerebrolysin in traumatic brain injury – a pilot study of neurotrophic and neurogenic agent in the treatment of acute traumatic brain injury, J Neurol Neurochirurgie Psychiatrie 2006;7:12-20.

[5] Alvarez X.A. et al., Positive Effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury, Int Clin Psychopharmacology 2003; 18:271-278.

[6] Muresanu DF, et al., A retrospective, multi-center cohort study evaluating the severityy-related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury, CNS Neurol Disord Drug Targets 2015; 14:587-99.

[7] Gauthier S., Proano J. V., Jia J., Froelich L., Vester J. C., Doppler E., Cerebrolysin in mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47.

[8] Alvarez XA., et al., A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol 2006;13:46-54.

[9] Ruether EJ, et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol 2001;16:253-263.

[10] Ruether Eet al. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994;27:23-40.

[11] Bae CY, et al. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc 2000;48:1566-1571.

[12] Xiao SF, et al. Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer’s disease. Clin Drug Investig 2000;19:43-53.